Cargando…
Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial
The state of immune activation may guide targeted immunotherapy in sepsis. In a double-blind, double-dummy randomized clinical study, 240 patients with sepsis due to lung infection, bacteremia, or acute cholangitis were subjected to measurements of serum ferritin and HLA-DR/CD14. Patients with macro...
Autores principales: | Leventogiannis, Konstantinos, Kyriazopoulou, Evdoxia, Antonakos, Nikolaos, Kotsaki, Antigone, Tsangaris, Iraklis, Markopoulou, Dimitra, Grondman, Inge, Rovina, Nikoleta, Theodorou, Vassiliki, Antoniadou, Eleni, Koutsodimitropoulos, Ioannis, Dalekos, George, Vlachogianni, Glykeria, Akinosoglou, Karolina, Koulouras, Vassileios, Komnos, Apostolos, Kontopoulou, Theano, Prekates, Athanassios, Koutsoukou, Antonia, van der Meer, Jos W.M., Dimopoulos, George, Kyprianou, Miltiades, Netea, Mihai G., Giamarellos-Bourboulis, Evangelos J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729870/ https://www.ncbi.nlm.nih.gov/pubmed/36384100 http://dx.doi.org/10.1016/j.xcrm.2022.100817 |
Ejemplares similares
-
Past history of stage I/II solid tumor malignancy impacts considerably on sepsis mortality: a propensity score matching analysis from the hellenic sepsis study group
por: Dimοpoulos, George, et al.
Publicado: (2019) -
ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients
por: Karakike, Eleni, et al.
Publicado: (2021) -
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
por: Giamarellos-Bourboulis, Evangelos J., et al.
Publicado: (2020) -
Presepsin as a diagnostic and prognostic biomarker of severe bacterial infections and COVID-19
por: Kyriazopoulou, Evdoxia, et al.
Publicado: (2023) -
Oral minocycline plus rifampicin versus oral linezolid for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: The AIDA open label, randomized, controlled Phase 4 trial
por: Kotsaki, Antigone, et al.
Publicado: (2022)